Liprolog Mix25

Insulin lispro, the active ingredient in Liprolog Mix25, is a rapid‑acting insulin analog presented as a subcutaneous injectable formulation for subcutaneous use. It is used to lower blood glucose in patients with type 1 and type 2 diabetes mellitus. It acts quickly after injection, mimicking the body’s natural insulin response to meals.

GNH USA supplies Liprolog Mix25 as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable logistics for global distribution.

Insulin lispro is a rapid‑acting insulin analog used to manage hyperglycaemia in diabetes.

- Type 1 diabetes mellitus: improves post‑prandial glucose control. - Type 2 diabetes mellitus: assists in achieving glycaemic targets when combined with other therapies. - Meal‑time insulin supplementation: provides rapid glucose lowering after meals.

Common Side Effects: - Hypoglycaemia: symptoms of low blood sugar such as shakiness, sweating, and confusion. - Injection site reactions: redness, swelling, or itching at the injection site. - Weight gain: modest increase in body weight with chronic use. - Lipodystrophy: localized changes in subcutaneous fat. - Localized allergic reaction: itching or rash at injection site.

Serious or Rare Side Effects: - Severe hypoglycaemia: profound low blood glucose requiring assistance. - Anaphylaxis: systemic allergic reaction with difficulty breathing or swelling. - Hypokalemia: low potassium levels, especially with high insulin doses. - Insulin antibody formation: may alter insulin effectiveness. - Acute pancreatitis: rare inflammation of the pancreas.

Before initiating therapy, consider individual patient factors and monitor regularly. - Dose individualisation: titrate according to blood glucose monitoring and clinical response. - Hypoglycaemia risk: educate patients on recognising and treating low blood sugar. - Renal impairment: adjust dose as reduced clearance may increase effect. - Pregnancy and lactation: use only if benefits outweigh potential risks. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Insulin lispro may interact with several concomitant medications.

Major Interactions (Avoid): - Sulfonylureas: additive hypoglycaemia risk. - Beta‑blockers: may mask hypoglycaemia symptoms.

Moderate Interactions (Monitor Closely): - ACE inhibitors: can enhance insulin sensitivity, requiring dose adjustment. - Thiazide diuretics: may increase blood glucose levels. - Corticosteroids: may necessitate higher insulin doses due to hyperglycaemic effect.